Abstracts Archive - Page 484 of 1683 - ATC Abstracts

2020 American Transplant Congress
Ten Year Results of a Single Center Study of Rabbit Anti-Thymocyte Globulin Compared to Alemtuzumab Induction in Simultaneous Pancreas-Kidney Transplantation
V. Gurram, K. Gurung, G. Orlando, A. Farney, J. Rogers, C. Jay, W. Doares, S. Kaczmorski, A. Reeves-Daniel, A. Mena-Gutierrez, M. Gautreaux, R. Stratta
Abdominal Transplant Surgery, Wake Forest Baptist Health, Winston Salem, NC
*Purpose: The study purpose was to analyze 10-year outcomes of depleting antibody induction agents in simultaneous pancreas-kidney transplant (SPKT) at a single center*Methods: From 2/02…
2020 American Transplant Congress
Ion AmpliSeq RNA Expression Panel Evaluated by Next-Generation Sequencing (NGS) Can Detect Genes in Human Formalin-Fixed Paraffin-Embedded Kidney Biopsies to Predict T Cell and Antibody Mediated Rejection in Renal Allografts
P. Ruiz¹, E. Margolles-Clark¹, G. Guerra², A. Mattiazzi², M. Ortigosa-Goggins², G. Ciancio¹, L. Chen¹, G. Burke¹
¹Surgery, University of Miami, Miami, FL, ²University of Miami, Miami, FL
*Purpose: Optimization of effective anti-rejection therapies to prevent allograft rejection and to minimize drug toxicity may be aided by utilizing in situ biomarkers for detection…
2020 American Transplant Congress
Value of dd-cfDNA When Considering Recipient Ethnicity to Further to Help Risk Stratify Transplant Recipients
A. Langone¹, B. Fischbach², D. Cohen³
¹Vanderbilt Health, Nashville, TN, ²Baylor Scott & White Health, Fort Worth, TX, ³Columbia University, New York, NY
*Purpose: Within the modern era of kidney transplantation, African American (AA) transplant recipients continue to experience disproportionately higher rates of allograft loss. A combination of…
2020 American Transplant Congress
Five Year Patient Important Outcomes of Treated Acute Rejections Diagnosed with Protocol and Clinical Biopsy after Pancreas Transplant Alone for Type 1 Diabetes
Y. C. Kudva, S. R. Rizvi, R. Kaur, B. H. Smith, S. Batthula, P. G. Dean, A. Kukla, W. K. Kremers, M. D. Stegall
Mayo Clinic, Rochester, MN
*Purpose: STUDY PURPOSE: Acute rejection (AR) after Pancreas Transplant alone (PTA) continues to be a significant morbidity. We compared the outcomes of PTA recipients treated…
2020 American Transplant Congress
Donor-Derived Cell-Free DNA Levels During Early Rejection after Kidney Transplant May Be Impacted by Type of Induction Agent Received
M. Gillespie, K. Lim, A. Vo, E. Huang, N. Ammerman, A. Peng, R. Najjar, S. Sethi, S. Jordan
Cedars-Sinai, Los Angeles, CA
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) is an injury biomarker that detects rejection in kidney transplant recipients (KTR). It is reported as % cfDNA from the…
2020 American Transplant Congress
The Use of dd-cfDNA as a Predictive Tool for Future Proteinuria
S. Jordan¹, P. Sood², J. Bromberg³, D. Brennan⁴
¹Cedars-Sinai, Los Angeles, CA, ²University of Pittsburgh Medical Center, Pittsburgh, PA, ³University of Maryland, Baltimore, MD, ⁴The Johns Hopkins Hospital, Baltimore, MD
*Purpose: Most allografts with proteinuria >1500 mg/dL have new glomerular pathology. In contrast, lower levels of proteinuria are generally associated with non-glomerular, nonspecific histologic changes.…
2020 American Transplant Congress
Risk Factors for Failing Native Kidney Function after Successful PTA
A. Gruessner, S. Saggi, J. Renz, R. Gruessner
SUNY Downstate Medical Center, Brooklyn, NY
*Purpose: Patients with labile diabetes and good kidney function are often advised to wait until kidney function deteriorates and then undergo a SPK rather than…
2020 American Transplant Congress
Clinical and Demographic Factors Affecting Patient and Graft Survival in Pancreas Transplant Recipients: The Efispan Study
P. Ventura-Aguiar¹, M. Cabello², I. Beneyto³, D. Navarro Cabello⁴, G. Tabernero⁵, A. Alonso⁶, J. Ruiz⁷, S. Llorente⁸
¹Nephrology and Kidney Transplantation, Hospital Clinic Barcelona, Barcelona, Spain, ²Department of Nephrology, Hospital Carlos Haya, Malaga, Spain, ³Department of Nephrology, Hospital La Fe, Valencia, Spain, ⁴Department of Nephrology, Hospital Reina Sofía, Cordoba, Spain, ⁵Department of Nephrology, Hospital Universitario de Salamanca, Salamanca, Spain, ⁶Department of Nephrology, Hospital Universitario de A Coruña, A Coruña, Spain, ⁷Department of Nephrology, Hospital Marqués de Valdecilla, Santander, Spain, ⁸Department of Nephrology, Hospital Virgen de la Arrixaca, Murcia, Spain
*Purpose: Pancreas transplantation is an established treatment for diabetic patients with end-stage renal disease. Graft outcomes have improved in the last decades, but data regarding…
2020 American Transplant Congress
Voriconazole Associated Adverse Drug Events and Drug Monitoring in Lung Transplant Recipients
C. Y. Luo¹, R. G. Nador², R. D. Levy², J. Yee², L. Wei², N. Partovi¹
¹Vancouver General Hospital, Vancouver, BC, Canada, ²University of British Columbia, Vancouver, BC, Canada
*Purpose: Voriconazole is the drug of choice for prophylaxis and treatment of Aspergillus infection in lung transplant ( LTx) recipients. Voriconazole has a narrow therapeutic…
2020 American Transplant Congress
The Role of Antigen Presentation in B Regulatory Cell Function
A. Cuenca¹, N. Feeney², K. Deng², Q. Fu², G. Huai², C. Rickert², K. Lee², J. Markmann²
¹Boston Children's Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, MA
*Purpose: B regulatory cells (B regs) represent a subset of B cells with non-canonical regulatory function. The majority of effort has been focused on the…